Skip to content
DraconiticResearch
Search Sources API
201,683 studies31 sourcesUpdated 47 min ago
Peer-reviewedCC BY 4.0Nutrients

Changes in Eating Behavior and Food Preferences After Semaglutide or Tirzepatide Initiation: A Prospective Observational Pilot Study

  • Elisabetta Camajani1,2
  • Francesco Frigerio1,2
  • Chiara Quattrini1
  • Valentina Franzese1,3,4
  • Andrea Armani1,2
  • Stefania Gorini1,2
  • Tiziana Filardi1,2
  • Alessandra Feraco1,2
  • Massimiliano Caprio1,2
  • Mauro Lombardo1
4 affiliations
  1. 1Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Open University, Via di Val Cannuta, 247, 00166 Rome, Italy
  2. 2Laboratory of Cardiovascular Endocrinology, IRCCS San Raffaele Roma, Via di Val Cannuta, 247, 00166 Rome, Italy
  3. 3Campus Bio-Medico University of Rome, 00128 Rome, Italy
  4. 4Biochemical Pharmacology, William Harvey Research Institute, Queen Mary University of London, London E1 4NS, UK
Open at sourceDOICite

Abstract

Background: This pilot study evaluated changes in eating behavior, appetite, and dietary habits during semaglutide or tirzepatide treatment in adults with obesity. Methods: In this prospective observational study, 38 non-diabetic adults with obesity (mean age 56.1 ± 11.3 years; 73.7% female; BMI 32.7 ± 4.5 kg/m2) initiating semaglutide (n = 21) or tirzepatide (n = 17) were assessed at baseline and after 3 months. Clinical parameters and self-reported eating behaviors were evaluated using standardized measurements and a study-specific questionnaire. Results: Mean body weight decreased by 7.2 ± 4.9 kg (p < 0.001), and systolic blood pressure decreased by 6.1 ± 6.3 mm Hg (p < 0.001). Cravings for sweet and savory foods, difficulty resisting hunger between meals, and daily meal frequency decreased, whereas perceived meal-induced satiety increased (all p ≤ 0.005). A substantial reduction in meal portion size was reported by 84.2% of participants. Reported food-group consumption changed, but improved overall dietary quality was not established. Conclusions: Over 3 months, incretin-based treatment was accompanied by weight loss and changes in self-reported eating behavior. The observational design, absence of a control group, and unvalidated questionnaire limit interpretation. Larger controlled studies using validated measures are warranted.

Related

  1. Post-Initiation Care Patterns and Weight Loss With Semaglutide and Tirzepatide for Obesity in Clinical Practice
    H. Yang, C. Kim, J. S. Ross +11
    medRxivPreprintCC BYFull textCardiovascular medicinemedRxiv
  2. Cutaneous Adverse Events Associated with Semaglutide, Liraglutide and Tirzepatide: A Systematic Review
    Aditya K. Gupta, Elizabeth M. Teasell, Renata F. Magalhães +2
    Medical sciences (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Symptom burden profiles and applied medication strategies in the days before and after initiation of palliative sedation in advanced cancer patients: an international prospective multicentre observational study (PALSED)
    Maaike Rijpstra, Evelien Kuip, Alazne Belar +9
    Supportive Care in CancerPeer-reviewedCC BY 4.0Full textEpidemiology & public healthPMC
  4. No decline in functional status or cognitive function during the first year after treatment initiation for early-stage breast cancer in women aged 75 years and older: a prospective observational matched cohort study
    W. G. van der Plas-Krijgsman, J. W. Blom, M. G. M. Derks +12
    medRxivPreprintCC BYFull textOncologymedRxiv
  5. Longitudinal psychosocial burden, quality of life, and digital supportive care preferences before and after CAR T-cell therapy: a prospective single-center observational study
    Anna Fleischer, Sabine-Anna Bergert, Patrick-Pascal Strunz +12
    BMC CancerPeer-reviewedCC BY 4.0Full textOncologyPMC

Cite

BibTeXRIS
BibTeX
@article{camajani2026changes,
  title = {{Changes in Eating Behavior and Food Preferences After Semaglutide or Tirzepatide Initiation: A Prospective Observational Pilot Study}},
  author = {Elisabetta Camajani and Francesco Frigerio and Chiara Quattrini and Valentina Franzese and Andrea Armani and Stefania Gorini and Tiziana Filardi and Alessandra Feraco and Massimiliano Caprio and Mauro Lombardo},
  journal = {Nutrients},
  year = {2026},
  month = nov,
  doi = {10.3390/nu18213675},
  url = {https://www.mdpi.com/2072-6643/18/21/3675},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Changes in Eating Behavior and Food Preferences After Semaglutide or Tirzepatide Initiation: A Prospective Observational Pilot Study
AU  - Elisabetta Camajani
AU  - Francesco Frigerio
AU  - Chiara Quattrini
AU  - Valentina Franzese
AU  - Andrea Armani
AU  - Stefania Gorini
AU  - Tiziana Filardi
AU  - Alessandra Feraco
AU  - Massimiliano Caprio
AU  - Mauro Lombardo
PY  - 2026
DA  - 2026/11/05
JO  - Nutrients
DO  - 10.3390/nu18213675
UR  - https://www.mdpi.com/2072-6643/18/21/3675
AB  - Background: This pilot study evaluated changes in eating behavior, appetite, and dietary habits during semaglutide or tirzepatide treatment in adults with obesity. Methods: In this prospective observational study, 38 non-diabetic adults with obesity (mean age 56.1 ± 11.3 years; 73.7% female; BMI 32.7 ± 4.5 kg/m2) initiating semaglutide (n = 21) or tirzepatide (n = 17) were assessed at baseline and after 3 months. Clinical parameters and self-reported eating behaviors were evaluated using standardized measurements and a study-specific questionnaire. Results: Mean body weight decreased by 7.2 ± 4.9 kg (p < 0.001), and systolic blood pressure decreased by 6.1 ± 6.3 mm Hg (p < 0.001). Cravings for sweet and savory foods, difficulty resisting hunger between meals, and daily meal frequency decreased, whereas perceived meal-induced satiety increased (all p ≤ 0.005). A substantial reduction in meal portion size was reported by 84.2% of participants. Reported food-group consumption changed, but improved overall dietary quality was not established. Conclusions: Over 3 months, incretin-based treatment was accompanied by weight loss and changes in self-reported eating behavior. The observational design, absence of a control group, and unvalidated questionnaire limit interpretation. Larger controlled studies using validated measures are warranted.
SN  - 2072-6643
ER  -